The epidemiologist and immunologist Michael Mina called Kennedy’s move a “code red” for vaccines in America. Reportedly, none ...

The FDA has expanded the approval of mResvia to include active immunization in high-risk individuals 18 through 59 years of age.

Warren and Duckworth demanded Kennedy make the review public, alongside a similar review the department cited when it cut ...

Vaccine businesses seen as valuable parts of pharma groups but government hostility could deter future developments ...

The Moderna vaccine is one of the vaccines currently available in the United States and other countries to protect against COVID-19, which is the disease the novel coronavirus causes. Clinical ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

President Donald Trump's administration last month canceled a $590-million contract awarded to Moderna in January by outgoing ...

NB.1.8.1 is one of the latest variants of COVID-19, a "slightly upgraded version" of the LP.8.1 variant that is prominent ...

A leading infectious disease expert and one of the nation’s foremost COVID-19 researchers has voiced deep concerns about the ...

Pfizer’s 7%+ yield is tempting, but rising political, regulatory, and business risks threaten its stability and growth ...

BioNTech said in 2022 that it faced “threats of a groundless patent infringement suit” from a company that was “unable to ...

While the outlook for vaccines in the US looks bleak under the current administration, the UK Government is pressing ahead ...